Contract analysis

I. Executive Summary This memorandum analyzes the qualified cost-sharing arrangement ("CSA") agreement executed effective July 1, 2012, between Penterra Pharmaceuticals Corp. ("PPC") and Penterra Biopharma International DAC ("PBI") for compliance with the regulatory requirements governing qualified cost-sharing arrangements under Treasury Regulation § 1.482-7. The analysis is undertaken in the context of an ongoing e

II. Background A. Corporate Structure The relevant entities in the Penterra group for purposes of this analysis are as follows: Penterra Pharmaceuticals Corp. ("PPC"). PPC is a Delaware corporation, publicly traded on the Nasdaq Stock Market under ticker symbol PPCA, with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC operates as a specialty pharmaceu

III. Regulatory Framework — Treas. Reg. § 1.482-7 A. Overview of Qualified Cost-Sharing Arrangement Requirements The regulatory framework governing cost-sharing arrangements between controlled parties is set forth in Treasury Regulation § 1.482-7, which was substantially revised in 2011 (the "2011 Temporary Regulations") and finalized in 2012 (T.D. 9568, 76 Fed. Reg. 80082 (Dec. 22, 2011)). The regulations define the

IV. Analysis of Key CSA Terms and Regulatory Compliance A. Controlled Participant Eligibility — Treas. Reg. § 1.482-7(b)(1) Treasury Regulation § 1.482-7(b)(1) requires that each controlled participant in a CSA satisfy three conditions: (i) the participant must be a "controlled taxpayer" within the meaning of Treas. Reg. § 1.482-1(i)(5), meaning it must be one of two or more organizations, trades, or businesses owned

V. Administrative Requirements — Treas. Reg. § 1.482-7(k) A. Written Agreement Treasury Regulation § 1.482-7(k)(1) requires that a qualified cost-sharing arrangement be set forth in a written agreement that is in effect before the first date on which any IDA cost is incurred. The written agreement must describe the scope of the IDA, the controlled participants, the territories, the cost-sharing methodology, and the t

VI. Economic Substance of PBI as CSA Participant Although the detailed economic substance analysis is the subject of a separate memorandum being prepared by Nazari (anticipated completion: August 18, 2022), the CSA compliance analysis must address PBI's qualification as a bona fide controlled participant, as the IRS has specifically challenged PBI's economic substance as part of its examination of the CSA. This secti

1. Headcount and Growth. PBI employed 185 individuals as of December 31, 2020, representing a more than threefold increase from its initial headcount of 52 employees at the time of its establishment in 2012. This growth trajectory reflects a genuine and sustained build-out of PBI's operational capabilities over the life of the CSA.

2. Management and Governance. PBI's Managing Director, Aidan Naughton, is based in Dublin and exercises day-to-day management authority over PBI's operations. PBI's board of directors held 42 board meetings in Dublin during the 2017–2020 examination period, comprising quarterly meetings plus special sessions convened as needed to address significant strategic, regulatory, and commercial matters.

3. Physical Presence. PBI occupies approximately 18,000 square feet of office space at Claremont House, Sandyford Business Park, Dublin, which houses PBI's regulatory affairs, medical affairs, commercial strategy, supply chain, and administrative personnel.

4. Regulatory Expenditures. PBI incurred cumulative regulatory expenditures and submission costs of approximately €47.2 million during the 2017–2020 examination period, reflecting PBI's direct and substantive involvement in obtaining and maintaining marketing authorizations across non-Americas markets, including the European Union, Japan, China, Australia, and numerous other countries.

5. Commercial Decision-Making. PBI made independent pricing decisions across 68 country markets within its non-Americas territory. These pricing decisions involved the evaluation of local market conditions, reimbursement frameworks, competitive dynamics, and regulatory requireme